VYNE: VYNE Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for VYNE
Across the 3 sessions after earlier VYNE headlines, the stock closed higher 2 times and lower 1 times, with a median move of 5.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VYNE | SPY |
|---|---|---|---|
| Jul 10, 2026 | VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience | -5.1% | +0.4% |
| Dec 17, 2025 | VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement | +49.0% | -1.1% |
| Nov 6, 2025 | VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update | +4.6% | -1.1% |
Quantisnow market dataNASDAQ
VYNE
VYNE Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for VYNE
Full VYNE profile on Quantisnow Follow VYNE and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time